Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.
The pathophysiological triggers responsible for the secretion of copeptin are incompletely understood. It appears that it is released in a proportional manner with biologically active vasopressin from the posterior neurohypophysis after their synthesis in the hypothalamus. [1] [2] [3] [4] [5] [6] [7] [8] [9] Copeptin can be used as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders, including acute myocardial infarction (AMI). 3, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] As a single variable, it has only modest diagnostic accuracy for AMI. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, as it is elevated already very early in AMI, while cardiac troponin (cTn) as a structural protein of cardiomyocytes is released into the circulation in a time-dependent fashion, the use of copeptin within a dual-marker strategy together with cTn has a strong pathophysiological rationale. This approach has been extensively evaluated to rule out AMI as a way to overcome the delay in release of cTn, especially when less sensitive conventional cTn assays are used. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Since copeptin is elevated in so many conditions, it cannot be used to rule in AMI.
Use of copeptin for rapid rule-out of acute myocardial infarction Need for early rule-out of AMI
As the majority of patients presenting with suspected AMI will ultimately not have AMI, but often non-cardiac and benign disorders such as musculoskeletal pain, anxiety disorder, pleuritis, or gastroesophageal reflux, the ability to rapidly exclude AMI has major medical as well as economic importance. Because of the limited sensitivity of the electrocardiogram (ECG) and conventional cTn assays, the safe rule-out of AMI requires a second cTn sample and a second ECG recording 6-12 h after presentation if a conventional cTn assay is used. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] A shorter, 1 h or 3 h, protocol can be used with high sensitivity assays. 23, 25, 26 The delay in ruling out AMI can interfere with the detection of the underlying disease, increase patient anxiety, and is associated with substantial use of resources in the emergency department (ED), which contributes to ED crowding and its associated medical and economic harm. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 
Copeptin
Vasopressin has a very short half-life and is hard to measure. Copeptin is a more stable 39 amino acid peptide derived from the prohormone along with vasopressin and neurophysin 1. There are now analytically sound methods to precisely quantify copeptin after its release from the neurohypophysis, and possibly also from other organs. 27 Copeptin does not seem to be secreted from the heart. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Although insights into the exact pathophysiology of copeptin are still incomplete, the currently available data may be best summarized as suggesting that copeptin plasma concentrations in acute cardiovascular conditions reflect and quantify endogenous stress. As a signal, copeptin is therefore distinct from B-type natriuretic peptides, which reflect haemodynamic cardiac stress (end-diastolic wall stress). 28 Copeptin is not organ-specific, but rather is a non-specific marker of acute illness and disease severity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Among patients presenting with acute chest discomfort, copeptin plasma concentration are usually elevated in AMI and other acute cardiac conditions such as myocarditis and heart failure, but also in many non-cardiac conditions such as pneumonia and renal colic (Figure 1 ). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Copeptin is not elevated in patients with unstable angina. [11] [12] [13] [18] [19] [20] Dual-marker strategy for rapid rule-out of AMI By having a very different pathophysiological trigger with a time-course that is complementary to that of cTn as a marker of cardiomyocyte injury (Figure 2 ), copeptin may have some incremental diagnostic value in the early exclusion of AMI at the time of initial presentation. Its complimentary release kinetics to cTn is an important advantage as compared with other injury markers with similar kinetics to cTn, such as myoglobin and heart-type fatty-acid binding protein.
The use of copeptin together with cTn within a dualmarker strategy for rapid rule-out of AMI is the only indication for copeptin, for which the currently available data are sufficient to merit its clinical use. The dual-marker strategy Boxes represent interquartile ranges and whiskers display ranges (without outliers further than 1.5 interquartile ranges from the end of the box). AMI: acute myocardial infarction; CAD: coronary artery disease; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction Reprinted from Reichlin et al. 11 with permission from Elsevier.
is one of several well-validated biomarker-based strategies for the rapid rule-out of AMI 25, 26 and is the only one that uses a second blood biomarker measurement in addition to cTn. However, copeptin has no value for early rule-in of AMI. 29 Although earlier rule-out with the dual-marker strategy likely is associated with cost savings, the exact cost-effectiveness is unknown. This is at least in part due to the financial and organizational barrier of installing and running the copeptin analyser 24/7. Furthermore, the additional number of patients eligible for early discharge from the ED and the time savings are still unclear when the dual marker strategy is applied in clinical routine. 30, 31 Adequately designed health economic studies are needed, something that applies to all 'rapid rule-out' strategies. In settings where only a conventional cTn assay is available, the use of the dual-marker strategy is recommended for the rapid ruleout of AMI by current European Society of Cardiology (ESC) guidelines. 25 
Validation studies
Reichlin was the first to study this concept 10 years ago. 10, 11, 27 The initial observation that levels of copeptin seemed elevated in the vast majority of AMI patients led to the design of the first pilot study to test and confirm the hypothesis of the feasibility and safety of a dual-marker strategy. 10, 11 This novel approach is now supported by several large methodological robust diagnostic studies, metaanalyses summarizing their findings in more than 9000 patients, and a randomized management trial. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In the 14 diagnostic studies included in the latest metaanalysis, there was a total of 9244 patients with a mean age of 62 years, 64% were male and 18.4% were ultimately diagnosed with AMI. 15 Patients with AMI had a higher copeptin level than those without AMI (22.9 vs. 7.9 pmol/l, p<0.001). 15 As a single marker, cTn had better diagnostic accuracy than copeptin for AMI. However, the combination of copeptin with cTn compared with cTn alone significantly improved diagnostic accuracy as quantified by the area under the receiver-operating characteristics curve (AUC), sensitivity, negative predictive value (NPV) and negative likelihood ratio. Current data suggest that the sensitivity of the cTn assay used is critical for the incremental clinical value of copeptin. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The combination of copeptin provided substantial benefit with conventional cTn, but only a small benefit with sensitive cTn and only a very small benefit with high-sensitivity cTn (hs-cTn) when compared with hs-cTn alone (Figure 3 ). In addition, the AUC of copeptin in combination with hs-cTn taken (both from the blood sample at ED presentation) is lower as compared with the AUC of hs-cTn at presentation combined with the hs-cTn level 1h after ED presentation. Accordingly, a hscTn-only strategy seems to achieve higher AUC at 1h as compared with the dual-marker strategy at presentation.
Incremental value of copeptin when used in combination with conventional cTn
When used in conjunction with the well characterized conventional fourth generation cTnT, the added value of copeptin regarding diagnostic accuracy upon ED arrival is substantial. 11, 12 cTn assays with similar sensitivity to the conventional fourth generation cTnT assay are still widely used in 2017. While most of the large laboratory platforms used in Europe have implemented sensitive or hs-cTn assays in the last years, many institutions outside of Europe, Diagnostic accuracy of cTn alone and in combination with copeptin at presentation. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The incremental value of copeptin is substantial with conventional cTn, small with sensitive cTn and very small with hs-cTn when compared with hs-cTn alone.
cTn: cardiac troponin; hs-cTn: high-sensitivity cTn and nearly all point-of care cTn assays used world-wide, do not meet the criteria defining a sensitive or hs-cTn assay, the precise measurement around the 99th percentile of healthy individuals. [23] [24] [25] The increase in overall diagnostic accuracy (AUC) is to large extent driven by the increase in NPV and sensitivity for AMI. 11, 12 If the initial cTn level is below the 99th percentile and the copeptin level is below 10pmol/l, then the negative predictive value for AMI is very high (92-99%). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Used in conjunction with all other clinical information, including the 12-lead ECG, this information will allow rule-out of AMI without serial blood draws and prolonged ECG monitoring, and consideration of outpatient management in a substantial portion of patients presenting with acute chest pan (Case 1 in Supplementary Material online). The largest gain in diagnostic accuracy can be expected in early presenters ( Figure  4) . The current ESC guidelines recommend a dual-marker strategy for the early rule-out of AMI whenever conventional cTn is used. This recommendation is also based on the results of an open-label randomized management trial applying the dual-marker strategy in patients that most commonly were managed with a conventional cTn assay. 16 A total of 902 patients were randomly assigned to either standard care or a dual-marker strategy where patients with negative troponin and copeptin values at presentation were eligible for discharge after final clinical assessment. The proportion of major adverse cardiovascular events (MACEs; death, survived sudden cardiac death, AMI, rehospitalization for acute coronary syndrome, acute unplanned percutaneous coronary intervention, coronary artery bypass grafting, or documented life threatening arrhythmias) was assessed after 30 days. Intention to treat analysis showed a MACE proportion of 5.17% (95% confidence intervals (CI) 3.30-7.65%; 23/445) in the standard group and 5.19% (95% CI 3.32-7.69%; 23/443) in the copeptin group. In the copeptin group, 67.6% (305/451) were discharged from the ED as opposed to 12.0% (54/451) in the standard group (p<0.001) ( Figure 5 ). As the trial investigated the use of copeptin in conjunction with full clinical assessment, the crossover in the copeptin arm on the copeptin negative patients on the basis of physician action may have contributed to the similar event rate in both groups. Astute ED physicians overruled most of the false-negative copeptin levels by paying attention to all other clinical information appropriately and, thus, avoided inappropriate rule-out of AMI and/or discharge. It is mandatory to highlight that the same must be done when applying the dual-marker strategy, as well as all other rapid rule-out strategies, in clinical practice.
In order to have the copeptin level available at the same time as the cTn level, it seems justified to measure both biomarkers in all patients presenting with suspected AMI. An alternative concept is to restrict the measurement of copeptin to those patients who have normal cTn blood concentrations at presentation. This, however, would delay the availability of the copeptin result by at least 30 min, even if the measurement is performed from the remaining sample volume of the blood draw at presentation. If either marker is elevated, clinical management should continue with the standard operating procedures including ECG-monitoring until the second blood draw at 6 h.
Incremental value of copeptin when using hs-cTn
The clinical evaluation of hs-cTn assays at large occurred in parallel to that of copeptin. The use of hs-cTn assays has to a large extent overcome the sensitivity deficit of cTn at ED presentation. [23] [24] [25] [26] Therefore, the added value of copeptin to hs-cTn is much less obvious. Initial pilot studies investigating the combination of copeptin with hs-cTnT suggested that copeptin may still provide small incremental value upon ED arrival. 13, 19, 20, 22 In most of these studies overall diagnostic accuracy as quantified by the AUC was not increased or increased only marginally (e.g. from 0.90 to 0.91) by the additional use of copeptin. In contrast, when using pre-defined cut-off levels (the 99th percentile for cTn), the NPV showed a clinically relevant increase (e.g. from 96% to 99%). 13, 19, 20, 22 This suggests that the use of cut-off levels for hs-cTn below the 99th percentile can be expected to achieve the same NPV as the combination of hs-cTn at the 99th percentile together with a negative copeptin. 13, 19, 20, 22, 25, 26 In institutions using hs-cTn assays and the 99th percentile as the decision point for AMI as recommended in the universal definition of AMI, [23] [24] [25] further studies are required to convincingly establish a clinical relevant increase in diagnostic performance that would then justify routine clinical use. In addition, it is unlikely that copeptin can be cost-effective when used with hs-cTn.
How to use copeptin
As the copeptin assay is now becoming clinically available in more and more institutions, it is important for clinicians and laboratory physicians to be aware of the potential and the procedural details, as well as the possible challenges and caveats of using copeptin in clinical practice. [16] [17] [18] [19] [20] First, copeptin is not elevated in patients with unstable angina. [11] [12] [13] [18] [19] [20] Clinical presentation indicative of unstable angina requires further testing, possibly including coronary angiography or cardiac stress testing irrespective of copeptin blood concentration. Therefore, rapid rule-out of AMI should not be misinterpreted as the absence of coronary artery disease (Case 2 in Supplementary Material online). However, patients with suspected unstable angina and normal levels of cTn as well as low levels of copeptin are at very low risk of short-term mortality. [11] [12] [13] [18] [19] [20] Second, we do not see a justification to alter clinical management in patients with suspected non-cardiac causes of acute chest pain such as musculoskeletal pain, anxiety disorder, or gastroesophageal reflux and elevated levels of copeptin. Similarly, these elevations by themselves do not warrant any specific evaluation. Elevated blood concentrations occur in about 20% of patients with non-cardiac causes of acute chest pain, and are associated with some increase in longterm mortality, which however seems largely explained by aging, as well as known cardiac and non-cardiac comorbidities. 30 Third, like with similar rapid rule-out algorithms, 26 the rapid rule-out with the dual-marker strategy should only be used in conjunction with all available clinical information including detailed assessment of chest pain characteristics 31 and the ECG. 25, 26 Fourth, serial measurements of copeptin at 1h or 2h are not recommended in routine clinical use as serial measurements provide very little additional information, and are inferior to serial measurements of cTn. 21, 32 Fifth, we have to acknowledge that our current understanding of the exact pathophysiology of copeptin is still rather incomplete; for example, case reports indicate elevated blood concentrations also in patients presenting with vasovagal syncope to the ED (Case 3 in Supplementary Material online). It is unknown whether outcome differs in syncope patients with high copeptin blood concentrations as compared with those with normal levels. Future studies may provide important novel insights that will further refine the best possible clinical use of this relatively young biomarker. 33, 34 Sixth, as with any new biomarker, the optimal Figure 5 . Major adverse cardiac events (MACEs) proportions in study groups and in copeptin subgroups. Patients were randomized into copeptin and standard group, where MACE proportions were very similar. Copeptin results were only revealed to the treating staff in the copeptin group. In subgroups of copeptin-positive and copeptin-negative patients, MACE rates are higher in copeptin positives. MACE proportions are lowest in discharged copeptin-negative patients.
Reprinted from Mockel et al. 16 with permission from Oxford University Press.
cut-off value for copeptin within the dual-marker strategy has been a matter of debate. With the first generation copeptin assay 14 pmol/l was recommended as cut-off level; with the second generation, more sensitive, copeptin assays available in clinical practice, we recommend the use of 10 pmol/l as was done in the randomized trial. 21 
Gaps in knowledge and outlook
First, it is currently unknown how copeptin can best be combined with point-of-care assays for cTn. A point-ofcare assay for copeptin is in development, but not available yet. Pilot data suggest that it could help in the optimization of prehospital triage of patients with suspected AMI. 34 Second, no current diagnostic platform allows the simultaneous assay of both copeptin and cTnI/TnT. This, in turn, requires the use of two different platforms to obtain both results. Third, patients with complete left bundle branch block or paced ventricular complexes account for a small but very challenging minority of patients with suspected AMI. As both the ECG and cTn (due to chronic elevations due to underlying structural heart disease) have major limitations in these, copeptin is currently investigated in ongoing studies. Fourth, methodological sound health economic studies assessing the economic implications of using copeptin would be highly desirable.
In conclusion, the use of copeptin within a dual-marker strategy together with cTn for rapid rule-out of AMI is recommended whenever sensitive or hs-cTn assays are not available. A cut-off level of 10 pmol/l should be used. In institutions using sensitive or hs-cTn assays, ongoing research will need to more exactly define subgroups with relevant incremental values of copeptin before it can be recommended for routine use. Inherent limitations of the dual-marker strategy include the complexity of an additional biomarker, low positive predictive value for the combination of an elevated copeptin with a normal cTn, and the potential need for an additional analysis.
